The latest price target for Humacyte (NASDAQ:HUMA) was reported by D. Boral Capital on April 28, 2026. The analyst firm set a price target for $25.00 expecting HUMA to rise to within 12 months (a possible 2214.81% upside). 40 analyst firms have reported ratings in the last year.

The latest analyst rating for Humacyte (NASDAQ:HUMA) was provided by D. Boral Capital, and Humacyte maintained their buy rating.

There is no last upgrade for Humacyte

The last downgrade for Humacyte Inc happened on March 31, 2026 when Benchmark changed their price target from $10 to $1 for Humacyte Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on April 28, 2026 so you should expect the next rating to be made available sometime around April 28, 2027.

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a maintained with a price target of $25.00 to $25.00. The current price Humacyte (HUMA) is trading at is $1.08, which is out of the analyst’s predicted range.